Replimune finally wins approval, Q2 earnings wrap up, psychedelics stay in spotlight
From BioSpace · · 19 min
This plays from the publisher's own server. We do not host a copy.
Not rated yet
Description
After two rejections, Replimune has made it across the regulatory finish line with its twice-rejected therapy for advanced melanoma. Meanwhile, the last of the major pharmas, including Eli Lilly and Novo Nordisk, reported second quarter earnings, and psychedelics made headlines once again.